RxDoctor Payments Data

Tyler Hanson, MD

Internal Medicine · Yankton, SDNPI 1700800885

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 30.2% of the total. Reporting peaked in 2022 at $109 and has fallen 73.7% since, to $29 in 2025.

$292in general payments, 2019–2025

Across 12 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$88
  • Actelion Pharmaceuticals US, Inc.$59
  • Sun Pharmaceutical Industries Inc.$48
  • Viatris Specialty LLC$29
  • AstraZeneca$22
  • Biogen$19
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$292 in reported general payments places this provider in the 75th percentile of 178 internal medicine providers in South Dakota.

See all internal medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$585,403
Medicare patients
773
Services billed
31,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban595$363,041
OzempicSemaglutide99$109,411
OtezlaApremilast13$65,455
Invega SustennaPaliperidone Palmitate30$65,156
AristadaAripiprazole Lauroxil19$62,242
MounjaroTirzepatide47$48,913
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog138$48,562
JanuviaSitagliptin Phosphate40$39,396
JardianceEmpagliflozin33$39,361
XareltoRivaroxaban53$34,822
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$34,592
Tresiba Flextouch U-200Insulin Degludec20$33,379
MyrbetriqMirabegron92$33,008
FarxigaDapagliflozin Propanediol50$32,158
Potassium Chloride423$31,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$109,41199 claims
MerckJanuvia$13$39,39640 claims
AstraZenecaFarxiga$22$32,15850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 178 internal medicine providers in South Dakota.

Other internal medicine in Yankton

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →